Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments

被引:34
作者
Custurone, Paolo [1 ]
Di Bartolomeo, Luca [1 ]
Irrera, Natasha [2 ]
Borgia, Francesco [1 ]
Altavilla, Domenica [2 ]
Bitto, Alessandra [2 ]
Pallio, Giovanni [2 ]
Squadrito, Francesco [2 ]
Vaccaro, Mario [1 ]
机构
[1] Univ Messina, Dermatol, Dept Clin & Expt Med, Via C Valeria, I-98100 Messina, Italy
[2] Univ Messina, Dept Clin & Expt Med, Pharmacol, Via C Valeria, I-98125 Messina, Italy
关键词
vitiligo; interleukins; biologics; biological drugs; oxidative stress; autoimmune diseases; depigmentation; dermatoses; inflammation; skin; NEW-ONSET VITILIGO; NECROSIS-FACTOR-ALPHA; OXIDATIVE STRESS; SEGMENTAL VITILIGO; INTERFERON-GAMMA; SERUM-LEVELS; IFN-GAMMA; GENERALIZED VITILIGO; INFLIXIMAB TREATMENT; ALOPECIA-AREATA;
D O I
10.3390/ijms222111429
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vitiligo is a chronic autoimmune dermatosis of which the pathogenesis remains scarcely known. A wide variety of clinical studies have been proposed to investigate the immune mediators which have shown the most recurrency. However, such trials have produced controversial results. The aim of this review is to summarize the main factors involved in the pathogenesis of vitiligo, the latest findings regarding the cytokines involved and to evaluate the treatments based on the use of biological drugs in order to stop disease progression and achieve repigmentation. According to the results, the most recurrent studies dealt with inhibitors of IFN-gamma and TNF-alpha. It is possible that, given the great deal of cytokines involved in the lesion formation process of vitiligo, other biologics could be developed in the future to be used as adjuvants and/or to entirely replace the treatments that have proven to be unsatisfactory so far.
引用
收藏
页数:14
相关论文
共 117 条
[1]   Interleukin 17, Interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: A case- controlled study on eighty-four patients [J].
Abou Elela, Mostafa ;
Hegazy, Rehab A. ;
Fawzy, Marwa Mohamed ;
Rashed, Lalia A. ;
Rasheed, Hoda .
EUROPEAN JOURNAL OF DERMATOLOGY, 2013, 23 (03) :350-355
[2]   Serum levels of miRNA-21-5p in vitiligo patients and effects of miRNA-21-5p on SOX5, beta-catenin, CDK2 and MITF protein expression in normal human melanocytes [J].
Aguennouz, M'Hammed ;
Guarneri, Fabrizio ;
Oteri, Rosaria ;
Polito, Francesca ;
Giuffrida, Roberta ;
Cannavo, Serafinella P. .
JOURNAL OF DERMATOLOGICAL SCIENCE, 2021, 101 (01) :22-29
[3]  
Al-Shobaili HA, 2011, INT J HEALTH SCI-IJH, V5, P167
[4]  
AlGhamdi KM, 2012, J DRUGS DERMATOL, V11, P534
[5]   Drug-induced vitiligo: a case/non-case study in Vigibase(R), the WHO pharmacovigilance database [J].
Anthony, Norah ;
Bourneau-martin, Delphine ;
Ghamrawi, Sarah ;
Lagarce, Laurence ;
Babin, Marina ;
Briet, Marie .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2020, 34 (06) :736-742
[6]   Elevated serum level of interleukin-15 in vitiligo patients and its correlation with disease severity but not activity [J].
Atwa, Mona A. ;
Ali, Sara Mohammed Mohammed ;
Youssef, Nahed ;
Mahmoud Marie, Radwa El-Sayed .
JOURNAL OF COSMETIC DERMATOLOGY, 2021, 20 (08) :2640-2644
[7]   Vitiligo and Autoimmune Thyroid Disorders [J].
Baldini, Enke ;
Odorisio, Teresa ;
Sorrenti, Salvatore ;
Catania, Antonio ;
Tartaglia, Francesco ;
Carbotta, Giovanni ;
Pironi, Daniele ;
Rendina, Roberta ;
D'Armiento, Eleonora ;
Persechino, Severino ;
Ulisse, Salvatore .
FRONTIERS IN ENDOCRINOLOGY, 2017, 8
[8]   Role of interleukin-17 in the pathogenesis of vitiligo [J].
Bassiouny, D. A. ;
Shaker, O. .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2011, 36 (03) :292-297
[9]   Vitiligo: A Review [J].
Bergqvist, Christina ;
Ezzedine, Khaled .
DERMATOLOGY, 2020, 236 (06) :571-592
[10]   Increased systemic and epidermal levels of IL-17A and IL-1β promotes progression of non-segmental vitiligo [J].
Bhardwaj, Supriya ;
Rani, Seema ;
Srivastava, Niharika ;
Kumar, Ravinder ;
Parsad, Davinder .
CYTOKINE, 2017, 91 :153-161